Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vir Biotechnology, Inc.

4.91
+0.05001.03%
Volume:54.78K
Turnover:268.66K
Market Cap:682.08M
PE:-1.23
High:4.93
Open:4.86
Low:4.86
Close:4.86
52wk High:14.45
52wk Low:4.16
Shares:138.92M
Float Shares:94.55M
Volume Ratio:0.42
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0061
EPS(LYR):-3.8310
ROE:-46.22%
ROA:-24.73%
PB:0.72
PE(LYR):-1.28

Loading ...

Vir Biotechnology Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Yesterday

Director Vicki L. Sato Reports Disposal of Common Shares of Vir Biotechnology Inc

Reuters
·
Sep 04

Vir Biotechnology Initiated at Outperform by Evercore ISI Group

Dow Jones
·
Sep 03

Vir Biotechnology Shares Rise After Upgrade From BofA Securities

MT Newswires Live
·
Aug 28

Vir Biotechnology Raised to Buy From Neutral by B of A Securities

Dow Jones
·
Aug 28

Vir Biotechnology Inc : Bofa Global Research Raises to Buy From Neutral; Raises Price Objective to $14 From $12

THOMSON REUTERS
·
Aug 27

BofA Securities Upgrades Vir Biotechnology to Buy From Neutral, Price Target is $14

MT Newswires Live
·
Aug 27

Vir Biotechnology Inc. CEO to Participate in Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Aug 26

Stock Track | Vir Biotechnology Plummets 5.71% as Q2 Revenue Misses Estimates, Falling 61% Year-over-Year

Stock Track
·
Aug 07

Earnings Flash: (VIR) Vir Biotechnology Q2 Loss $0.80 Vs. FactSet Est. $0.72 Loss

MT Newswires Live
·
Aug 07

Stock Track | Vir Biotechnology Plunges 5.12% After-Hours on Q2 Earnings Miss

Stock Track
·
Aug 07

Stock Track | Vir Biotechnology Plunges 5.12% After Hours on Disappointing Q2 Earnings

Stock Track
·
Aug 07

Vir Biotechnology Q2 EPS $(0.80) Misses $(0.76) Estimate, Sales $1.21M Miss $2.38M Estimate

Benzinga
·
Aug 07

BRIEF-Vir Biotechnology Successfully Initiates All Trials In Eclipse Registrational Program

Reuters
·
Aug 06

Stock Track | Vir Biotechnology Soars 8% Pre-market on Successful Initiation of Chronic Hepatitis Delta Trials

Stock Track
·
Aug 06

Vir Biotechnology Successfully Initiates All Trials in Eclipse Registrational Program for Chronic Hepatitis Delta

THOMSON REUTERS
·
Aug 06

Vir Biotechnology Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta

Reuters
·
Aug 06

Director Vicki L. Sato Reports Disposal of Common Shares in Vir Biotechnology Inc

Reuters
·
Aug 05

Vir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment

Reuters
·
Jul 31

Vir Biotechnology Announces Launch of Phase 1 Clinical Trial for EGFR-Targeting T-Cell Engager VIR-5525 in Solid Tumors

Reuters
·
Jul 24